Alisa Femia is a Dermatology physician. OpenAlex indexes 128 publications with 1,888 citations (h-index 24).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
222 E 41st St Fl 16
New York, NY 100176739
Telephone
212-263-5889Provider last certified this registry record 10 Mar 2022.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca UK LimitedProgram year202519 payments$31,884openpaymentsdata.cms.gov ↗
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20259 payments$13,802openpaymentsdata.cms.gov ↗
- AbbVie Inc.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
31.6%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor15.8%Valacyclovir100%Part D<11 patientsAzole Antifungal15.8%Fluconazole100%Part D<11 patientsCardiovascular
21.1%Blood Viscosity Reducer21.1%Pentoxifylline100%Part D<11 patientsDermatology
18.4%Corticosteroid18.4%Triamcinolone Acetonide100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Anifrolumab in recalcitrant cutaneous dermatomyositis: A multicenter retrospective cohort study
Journal of the American Academy of Dermatology
2024 - Cardiovascular Risk Management in Patients Treated With Janus Kinase Inhibitors
Journal of Cardiovascular Pharmacology
2023 - Utility of magnetic resonance imaging in the diagnosis of eosinophilic fasciitis: A multicenter retrospective cohort study
Journal of the American Academy of Dermatology
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Hywel C Williams
University of Nottingham
Mohsen Afarideh, MD, MPH
Mayo Clinic
Brigitte Dréno
Centre National de la Recherche Scientifique
Giovanni Damiani
University of Milan
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”